Background:Gastrointestinal stromal tumors (GISTs) are a rare neoplasm, sometimes mimicking primary ovarian tumors (OTs) and/or metastasizing to the ovaries (M-OT). We performed a systematic literature review (SLR) of OTs and M-OTs, investigating differences in recurrence-free and overall survival.Methods:Our SLR was performed according to PRISMA guidelines, searching in Pubmed, Scopus, and Web of Science databases from inception until 21 April 2024.Results:Overall, 59 OTs (Group 1) and 21 M-OTs (Group 2) were retrieved. The absence of residual disease after surgery was achieved significantly in a higher percentage of patients with Group 1 GISTs (91.5%) compared with Group 2 GISTs (57.1%). Chemotherapy was more frequently administered to Group 2 patients (33% vs. 0%). Recurrence and deaths for disease were significantly more frequent in Group 2 than Group 1 cases (54.5% vs. 6.8%, and 37.5% vs. 9.8%, respectively).Conclusions:GISTs can rarely mimic primary ovarian cancers or even more rarely metastasize to the ovaries. Group 1 GISTs occurred in younger women, were not associated with elevated tumor markers, and had a better prognosis. In contrast, Group 2 GISTs occurred in older women, may exhibit elevated tumor markers, and presented a worse prognosis. However, no significant statistical difference for survival between the two studied groups was detected. Computed tomography scans can define the size of GISTs, which correlate to stage and prognostic risk classes. The gold standard treatment is complete surgical resection, which was achieved in almost all cases of Group 1 GISTs and in half of Group 2. Histopathology and immunohistochemistry are essential for the final diagnosis and guide chemotherapy treatment.
背景：胃肠道间质瘤（GIST）是一种罕见的肿瘤，有时会与原发性卵巢肿瘤（OT）相似，或转移至卵巢（M-OT）。我们对OT和M-OT进行了系统性文献综述（SLR），以探究其在无复发生存期和总生存期方面的差异。 方法：我们的SLR遵循PRISMA指南，检索了Pubmed、Scopus和Web of Science数据库自建库至2024年4月21日的文献。 结果：共纳入59例OT（第1组）和21例M-OT（第2组）。与第2组GIST患者相比，第1组GIST患者术后无残留病灶的比例显著更高（91.5% vs. 57.1%）。第2组患者接受化疗的频率更高（33% vs. 0%）。第2组患者的疾病复发率和疾病相关死亡率均显著高于第1组（分别为54.5% vs. 6.8% 和 37.5% vs. 9.8%）。 结论：GIST很少会与原发性卵巢癌相似，转移至卵巢的情况则更为罕见。第1组GIST患者年龄较轻，肿瘤标志物未见升高，预后较好。相比之下，第2组GIST患者年龄较大，可能出现肿瘤标志物升高，预后较差。然而，两组间的生存率未发现显著统计学差异。计算机断层扫描可确定GIST的大小，这与肿瘤分期和预后风险分级相关。完全手术切除是标准治疗方案，第1组GIST患者几乎全部实现，第2组患者中约半数实现。组织病理学和免疫组化对于最终诊断和指导化疗至关重要。
肿瘤(癌症)患者之家